Home Prescribing Information         Patient Information         Important Safety Information        Consumer Site   
Clinical Information
ED & High Cholesterol
ED & Diabetes
Treatment Toolkit
 
LEVITRA® (Vardenafil HCl)
ED & High Blood Pressure
For Your ED Patients With High Blood Pressure, LEVITRA May Be the Answer

LEVITRA is indicated to treat ED.

Hypertension serves as a risk factor for cardiovascular disease and for erectile dysfunction.16,17
In fact, ED is more prevalent in patients with hypertension than within the general male population.2,3

In a survey of 2912 men, 26% of men with high blood pressure reported having ED, while only 10% without high blood pressure or other comorbidities had ED.3

 

LEVITRA Improved Erectile Function vs Placebo Over 12 Weeks
In a study of men with ED and treated hypertension, LEVITRA significantly improved patients’ ability (83%) to achieve erections hard enough for intercourse (SEP2) vs placebo 6
ED And High Blood Pressure

LEVITRA and Blood Pressure Medications
Improvement in erectile function with LEVITRA was unaffected by different classes of antihypertensive medication.
 
Mean SEP3 success rate in patients taking concomitant ACE inhibitors

ED And High Blood Pressure
 
   Back to Top
 
Mean SEP3 success rate in patients taking concomitant beta-blockers
 
ED And High Blood Pressure
LEVITRA:
 
  • Is indicated for the treatment of ED and works for most men who have high blood pressure. In a study of men with ED and treated hypertension, LEVITRA significantly improved patients’ ability (83%) to achieve erections hard enough for intercourse (SEP2) vs placebo6
  • Works for most men who are also taking one or more types of blood pressure medication6
 
Important Safety and Dosing Information

LEVITRA (vardenafil HCl) is a prescription medicine that is indicated to treat erectile dysfunction (ED). Consistent with the effects of PDE5 inhibition, administration of LEVITRA with nitrates and nitric oxide donors is contraindicated.

Caution is advised when PDE5 inhibitors, including LEVITRA, are used concomitantly with stable alpha-blocker therapy, because of the potential for lowering blood pressure.

LEVITRA is not recommended for patients with uncontrolled hypertension (>170/110 mmHg).

In men for whom sexual activity is not recommended because of their underlying cardiovascular status, any treatment for erectile dysfunction, including LEVITRA, generally should not be used.

In patients taking certain CYP3A4 inhibitors (eg, ritonavir, indinavir, saquinavir, atazanavir, ketoconazole, itraconazole, erythromycin, and clarithromycin), lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended. See prescribing information for LEVITRA for dosing guidance.

In clinical trials, the most commonly reported adverse events with LEVITRA were headache, flushing, and rhinitis. Adverse events were generally transient.

Nonarteritic anterior ischemic optic neuropathy (NAION), has been reported rarely postmarketing in temporal relationship with the use of PDE5 inhibitors, including LEVITRA. Sudden loss of hearing, sometimes with tinnitus and dizziness, also has been reported rarely in temporal association with the use of PDE5 inhibitors, including LEVITRA. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including LEVITRA, and seek prompt medical attention in the event of sudden loss of vision or hearing.

The recommended starting dose of LEVITRA is 10 mg. Titrate up to 20 mg or down to 5 mg based on efficacy and side effects.

The maximum recommended dosing frequency is once daily.

LEVITRA is available in 2.5-mg, 5-mg, 10-mg and 20-mg tablets.

Please see complete Prescribing Information for 2.5-mg, 5-mg, 10-mg, and 20-mg LEVITRA.
[Requires Adobe® Reader® - click here to download].

   Adobe is a registered trademark of Adobe Systems Incorporated.

This site is intended for US healthcare professionals only.

© 2004-2008 Bayer Pharmaceuticals Corporation. All Rights Reserved. GlaxoSmithKline and Schering Corporation.



Legal Notices | Privacy Statement | Contact Us | Site Map | Search | References

Bayer HealthCare Pharmaceuticals GlaxoSmithKline Schering-Plough